What Lambda Therapeutic does

Lambda Therapeutic Research Limited is a privately held, India-headquartered full-service Clinical Research Organization (CRO) and Biologics Contract Development and Manufacturing Organization (CDMO), founded in 1998 in Ahmedabad and operating across 7 global offices in India, the USA, Canada, the UK, Spain, and Poland with a workforce of 1,200+ professionals. The company delivers end-to-end clinical research services spanning Phase I–IV trials, bioanalytical laboratory services, regulatory affairs, biostatistics and data management, medical writing, pharmacovigilance (including EU/UK QPPV coverage), medical imaging, eTMF, and quality assurance — supported by five proprietary technology platforms (BizNET EDC, IMPTrack, KnowledgeNET, Biolyte, and QEdge eQMS) built and maintained since 2011 and compliant with 21 CFR Part 11 and EU Annex 11.

Its revenue model is professional-services, project-based, and multi-year, with custom pricing negotiated by study complexity, therapeutic area, phase, and patient/site count; the customer base spans global pharmaceutical innovators, generic manufacturers, biotechs, and biosimilar developers, with explicit depth in oncology (65+ trials, 6,000+ patients across 900+ sites) and biosimilars (15+ molecules including Adalimumab, Bevacizumab, Rituximab, Trastuzumab, and Denosumab). Go-to-market is enterprise field sales plus inside sales across regional offices, an RFP submission portal, and active presence at industry events such as CPHI. Lambda's commercial moat rests on a 25-year regulatory track record — 100+ international regulatory inspections cleared, zero 483s on multiple US FDA visits, and continuous CAP (since 2005) and GLP (since 2014) certifications — together with 290+ clinical trials completed across 15+ therapeutic domains. Lambda Therapeutic Research is independent and family-led, with Bindi Chudgar as Founder and Managing Director and no disclosed institutional ownership or post-2010 M&A activity beyond the 2010 Biovail CRD acquisition.

Name

Lambda Therapeutic

Legal name

Lambda Therapeutic Research Limited

Website

https://lambda-cro.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Lambda Therapeutic Research is a privately held, India-headquartered full-service CRO and Biologics CDMO serving global pharma innovators, generic manufacturers, biotechs, and biosimilar developers with end-to-end Phase I–IV clinical research, bioanalytical, regulatory, and pharmacovigilance services across 7 global offices.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE), Clinical Trial Site Operations & Study Coordination (HLAGACAE), Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Clinical research services
• Bioequivalence studies
• Contract research organization
• Pharmacokinetic analysis
• Clinical trial management

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Full-Service CRO Services: Comprehensive clinical research services spanning the entire drug development lifecycle from early-phase trials to Phase II-IV clinical trial management, regulatory affairs, biostatistics, data management, pharmacovigilance, medical writing, and quality assurance. Revenue generated through project-based service contracts with pharmaceutical and biotech clients.
2. CDMO Services (Contract Development and Manufacturing Organization): Biologics development and manufacturing services including process development, analytical services, and manufacturing support for biologic therapeutics and biosimilars.
3. Laboratory Services: Bioanalytical services including small molecule analysis, biomarker analysis, immunogenicity testing, pharmacokinetics (PK), cell-based assays, and method development/validation under GLP compliance.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Lambda Therapeutic Research is a contract research organization (CRO) that conducts clinical research services including bioequivalence and pharmacokinetic studies for pharmaceutical sponsors. The company provides end-to-end clinical trial management, supporting drug development programs from study design through bioanalytical analysis and regulatory submission.

Product overview

Lambda Therapeutic Research operates as a full-service Clinical Research Organization (CRO) and Biologics Contract Development and Manufacturing Organization (CDMO) offering comprehensive, end-to-end clinical research solutions. The portfolio consists of core service lines—Full-Service CRO Services and Biologics CDMO Services—supported by integrated modules including Early Phase Clinical Trials, Phase II-IV Clinical Trial Management, Regulatory Affairs, Medical Writing, Biostatistics & Data Management, Clinical Safety & Pharmacovigilance (including QPPV Services for EU & UK), Medical Imaging, eTMF, Quality Assurance, and Bioanalytical Labs. Technology infrastructure includes proprietary platforms—BizNET (EDC), IMPTrack, KnowledgeNET, Biolyte, and QEdge eQMS—that enable regulatory-compliant data management and quality oversight. Therapeutic expertise spans Oncology & Hematology (65+ trials), Biosimilar Development (15+ molecules), and multiple additional therapeutic areas. Services range from early-phase BA/BE studies through Phase IV post-marketing surveillance, with capabilities across 15+ therapeutic domains supported by operations in India, USA, Canada, UK, Spain, and Poland.

Differentiator

Problem solved

Functional benefit

Products and services

• Bioequivalence Studies
• Pharmacokinetic (PK) Studies
• Clinical Trial Management
• Bioanalytical Services

Quantifiable outcome

• 100+ international regulatory inspections and audits successfully completed
• +6 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Celerion: Celerion is a CRO specializing in early-phase clinical pharmacology, BA/BE, and bioanalytical services, directly comparable to Lambda's Mehsana BA/BE center and bioanalytical lab offering.
• Clinipace Worldwide: Clinipace is a mid-sized, tech-enabled CRO focused on emerging and mid-tier biotech sponsors, comparable to Lambda in customer profile and full-service Phase II-IV delivery.
• Veeda Clinical Research: Veeda is an India-headquartered CRO with strong BA/BE and bioequivalence capabilities, the most direct India-based peer to Lambda's early-phase and bioanalytical business.
• Medpace: Medpace is a mid-sized, therapeutically focused full-service CRO with strong oncology and biosimilar expertise, closely comparable to Lambda in target customers, trial mix, and science-led operating model.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-tier full-service CRO with strong CNS, oncology, and rare-disease capabilities, offering a similar Phase I-IV service portfolio to Lambda for biotech and pharma sponsors.
• Synteract: Synteract is a mid-tier CRO with deep biotech customer base and Phase I-IV services, a direct comparable to Lambda in size, customer profile, and therapeutic breadth.

Broad incumbents

• IQVIA: IQVIA is the largest global CRO and life-science services firm, offering Phase I-IV clinical operations, real-world evidence, and analytics that overlap directly with Lambda's full-service CRO business, but at materially larger scale.
• Parexel International: Parexel is a large, established CRO offering end-to-end clinical development, biopharma services, and technology to pharma/biotech sponsors worldwide, comparable in service mix to Lambda but with a much larger global footprint.
• ICON plc: ICON is a top-3 global CRO providing full-service Phase I-IV, biostatistics, laboratory, and consulting services, competing against Lambda for the same multinational pharma and biotech sponsors.
• Syneos Health: Syneos is a top-5 full-service CRO and contract commercial organization serving pharma and biotech with clinical development and commercialization services that mirror Lambda's full-service model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=AFcJBV5lMgo
• LinkedInlinkedin.com/company/lambda-therapeutic-research
• Instagraminstagram.com/lambdacro
• Xx.com/lambdacro

Compliance16 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lambda Therapeutic